Treatment of Osteopenia
For postmenopausal women with osteopenia, prioritize lifestyle interventions (calcium, vitamin D, weight-bearing exercise) as the foundation, and reserve pharmacologic treatment for those with moderate-to-severe osteopenia (T-score -2.0 to -2.5) who have additional fracture risk factors placing them in the high-risk category.
Risk Stratification is Essential
The critical first step is recognizing that osteopenia is not a uniform condition—it exists on a spectrum from mild (T-score -1.0 to -1.5) to severe (T-score -2.0 to -2.5). Most fractures in postmenopausal women actually occur in those with osteopenia rather than osteoporosis 1. Women with moderate-to-severe osteopenia face elevated fracture risks, particularly for hip and vertebral fractures 1.
Use country-specific fracture risk assessment tools (like FRAX) alongside T-scores to categorize patients into low, moderate, high, or very high fracture risk groups 2. This integrated approach—not T-score alone—should guide treatment decisions 3.
Universal Lifestyle Measures for All Patients with Osteopenia
Every patient with osteopenia requires these foundational interventions 2:
- Calcium intake: Target 1000-1200 mg daily from diet plus supplements if needed. Prefer dietary sources; keep supplemental calcium <1000 mg/day due to potential kidney stone risk 2
- Vitamin D: Ensure serum 25-hydroxyvitamin D levels ≥20 ng/mL (50 nmol/L), typically requiring 400-1000 IU daily supplementation 2, 3
- Exercise: Balance, functional, and resistance training twice weekly 3
- Fall prevention: Increasingly important with advancing age, as falls cause most fractures 4
- Lifestyle modifications: Smoking cessation, limit alcohol to moderate intake 5
When to Initiate Pharmacologic Treatment
Pharmacologic therapy is appropriate for osteopenic patients who meet high-risk criteria 6, 1:
High-Risk Indicators:
- T-score between -2.0 and -2.5 (moderate-to-severe osteopenia) PLUS
- 10-year fracture risk ≥20% on FRAX, OR
- Age ≥70 years with T-score ≤-2.5, OR
- Prior fragility fracture, OR
- Multiple clinical risk factors (family history of hip fracture, glucocorticoid use, smoking, excessive alcohol)
The 2023 American College of Physicians guideline specifically recommends an individualized approach for women >65 with osteopenia, balancing benefits against harms and costs based on baseline fracture risk 6.
Pharmacologic Treatment Options for High-Risk Osteopenia
First-Line: Bisphosphonates
Bisphosphonates are the preferred initial therapy due to lower cost and extensive long-term safety data 2, 6:
- Oral options: Alendronate or risedronate weekly
- Intravenous option: Zoledronic acid 5 mg annually (particularly useful for adherence concerns)
Evidence shows zoledronic acid may reduce clinical vertebral fractures in osteopenic women, though hip fracture data remain uncertain 6.
Alternative First-Line Options for Specific Populations
For younger postmenopausal women (<60 years or <10 years post-menopause) with osteopenia:
- Menopausal hormone therapy (MHT) prevents all fracture types and is appropriate when 2:
- Patient has bothersome vasomotor symptoms
- Low cardiovascular and thrombotic risk
- No contraindications (no prior MI, stroke, or breast cancer)
- Bisphosphonates/denosumab not appropriate
- Patient willing to take MHT
For women with high breast cancer risk:
- Raloxifene or bazedoxifene (SERMs) reduce vertebral fractures and provide breast cancer risk reduction 2
- Requires low DVT risk and bisphosphonates/denosumab not appropriate
Important Caveat About Treatment Duration
Once bisphosphonate therapy is initiated, reassess fracture risk after 3-5 years 2. Those at low-to-moderate risk can consider a "bisphosphonate holiday" (temporary discontinuation up to 5 years), while high-risk patients should continue therapy 2. During holidays, reassess every 2-4 years and reinitiate if BMD declines significantly or fracture occurs 2.
Special Populations
Men Over 70 with Osteopenia
Apply the same risk stratification approach. Bisphosphonates are appropriate for men with primary osteoporosis at high fracture risk, though evidence is extrapolated primarily from female studies 6. The recommendation strength is conditional due to limited direct evidence in males.
Patients Who Cannot Tolerate Standard Therapies
If bisphosphonates, SERMs, denosumab, and hormone therapy are all contraindicated or not tolerated, calcium and vitamin D supplementation alone is recommended to prevent hip fractures 2. This is particularly supported in elderly individuals (≥70 years) in residential care settings where 33% hip fracture risk reduction was demonstrated 2.
Common Pitfalls to Avoid
- Don't treat all osteopenia uniformly: Mild osteopenia (T-score -1.0 to -1.5) without additional risk factors typically requires only lifestyle measures, not pharmacotherapy
- Don't use calcium supplements >1000 mg/day: Associated with kidney stone risk 2
- Don't use high-dose intermittent vitamin D: Doses like 500,000 IU/year or 20,000 IU/week increase fall and fracture risk 2
- Don't stop denosumab abruptly: If used, requires transition to another antiresorptive to prevent rebound bone loss 2
- Don't forget fall risk assessment: Particularly critical in older adults where falls precipitate most fractures 4